Actively Recruiting
Phase II Study of Short-Course Radiotherapy Combined with CAPOX Chemotherapy, Serplulimab, and Bevacizumab as Preoperative Therapy for MSS Mid-Low Locally Advanced Rectal Cancer
Led by First Affiliated Hospital of Wenzhou Medical University · Updated on 2026-01-16
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a new combined treatment approach for patients with mid-low locally advanced rectal adenocarcinoma that is MSS-type. This phase II study evaluates the safety and early effectiveness of short-course radiotherapy followed by CAPOX chemotherapy together with serplulimab and bevacizumab as total neoadjuvant therapy. The study aims to clarify this combinations impact on tumor response, organ preservation, and patient quality of life. Participants receive a short-course radiotherapy regimen of 5 sessions with 5 Gy each using advanced targeting techniques. After a 7-day rest, they start cycles of CAPOX chemotherapy, including oxaliplatin intravenously and oral capecitabine. Alongside chemotherapy, serplulimab immunotherapy and bevacizumab targeted therapy are administered by infusion every three weeks for six cycles. Following neoadjuvant treatment, patients undergo imaging and endoscopy to plan further care, including possible surgical removal of the tumor. During the study, researchers assess tumor response through pathological examination after surgery, focusing on the complete response rate. Patients disease-free survival, overall survival, adverse events, and quality of life are also monitored using standardized questionnaires. The study expects to enroll about 30 patients from December 2025 to September 2027, with follow-up continuing to evaluate long-term outcomes.
CONDITIONS
Brief Title
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
Research Team
Y
Yifei Pan, Master's Degree in Medicine
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here